Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $11.30 USD
Change Today -0.29 / -2.50%
Volume 116.2K
As of 8:10 PM 03/31/15 All times are local (Market data is delayed by at least 15 minutes).

tokai pharmaceuticals inc (TKAI) Snapshot

Open
$11.47
Previous Close
$11.59
Day High
$11.68
Day Low
$11.10
52 Week High
09/17/14 - $30.00
52 Week Low
10/10/14 - $9.67
Market Cap
252.9M
Average Volume 10 Days
73.9K
EPS TTM
--
Shares Outstanding
22.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for TOKAI PHARMACEUTICALS INC (TKAI)

Related News

No related news articles were found.

tokai pharmaceuticals inc (TKAI) Related Businessweek News

No Related Businessweek News Found

tokai pharmaceuticals inc (TKAI) Details

Tokai Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel proprietary therapies for the treatment of prostate cancer and other hormonally-driven diseases in the United States. Its lead drug candidate includes galeterone, an oral small molecule drug candidate, which is in Phase II clinical trials for the treatment of castration resistant prostate cancer. The company was founded in 2004 and is based in Cambridge, Massachusetts.

17 Employees
Last Reported Date: 03/26/15
Founded in 2004

tokai pharmaceuticals inc (TKAI) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $422.0K
Compensation as of Fiscal Year 2013.

tokai pharmaceuticals inc (TKAI) Key Developments

Tokai Pharmaceuticals, Inc. Reports Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

Tokai Pharmaceuticals, Inc. reported consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported loss from operations of $6,261,000 compared to loss from operations of $5,549,000 for the same period a year ago. Net loss was $6,208,000 compared to $5,525,000 last year. Net loss attributable to common stockholders was $6,208,000 or $0.28 per basic and diluted share compared to $5,540,000 or $11.23 per basic and diluted share last year. For the year, the company reported loss from operations of $23,462,000 compared to loss from operations of $15,749,000 for the same period a year ago. Net loss was $23,296,000 compared to $15,725,000 last year. Net loss attributable to common stockholders was $23,296,000 or $3.60 per basic and diluted share compared to $15,819,000 or $38.02 per basic and diluted share last year.

Tokai Pharmaceuticals Expands Contract with Qiagen

Tokai Pharmaceuticals expanded its contract with Qiagen. The agreement has been expanded to develop and commercialise an AR-V7 companion diagnostic for use with galeterone, a multi-targeted, oral small molecule drug candidate. The product is being developed to treat castration-resistant prostate cancer that acts by actively disrupting AR signalling, the key driver of prostate cancer growth, via multiple mechanisms of action. Under the deal, Tokai will receive the exclusive right from Qiagen to its newly acquired circulating tumour cell enrichment technology for use with galeterone, which will be incorporated into the companion diagnostic already under development by Qiagen.

QIAGEN N.V. Announces New Partnership with Tokai Pharmaceuticals Inc

QIAGEN N.V. announced an important expansion of its portfolio of liquid biopsies through the acquisition of an innovative technology that enables enrichment and molecular analysis of circulating tumor cells (CTCs) from blood samples. The company also announced a new partnership with Tokai Pharmaceuticals Inc. to combine this new CTC technology with a molecular assay to co-develop and commercialize a companion diagnostic for Tokai's novel drug compound galeterone, which is in late-stage clinical trials for treatment of castration-resistant prostate cancer (CRPC). The non-invasive test will determine the expression of the AR-V7 biomarker, which in recent studies has demonstrated potential utility to guide therapy choice in CRPC patients. Financial terms for the AdnaGen acquisition and the Tokai partnership were not disclosed.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TKAI:US $11.30 USD -0.29

TKAI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TKAI.
View Industry Companies
 

Industry Analysis

TKAI

Industry Average

Valuation TKAI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 2.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TOKAI PHARMACEUTICALS INC, please visit www.tokaipharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.